Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

C-060

Supelco

Cyclobenzaprine hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C20H22ClN
Numéro CAS:
6202-23-9
Poids moléculaire :
311.85
Numéro CE :
200-659-6
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Forme

liquid

Caractéristiques

SNAP-N-SPIKE®, SNAP-N-SHOOT®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

Concentration

1.0 mg/mL in methanol (as free base)

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

clinical testing

Format

single component solution

Température de stockage

−20°C

Chaîne SMILES 

Cl.CN(C)CC\C=C1\c2ccccc2C=Cc3ccccc13

InChI

1S/C20H21N.ClH/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20;/h3-6,8-14H,7,15H2,1-2H3;1H

Clé InChI

VXEAYBOGHINOKW-UHFFFAOYSA-N

Informations sur le gène

human ... HTR2A(3356) , HTR2C(3358)

Description générale

Cyclobenzaprine is a muscle relaxant sold under the trade name Flexeril® to relieve skeletal muscle spasms and associated pain from acute musculoskeletal conditions. This Snap-N-Spike® Reference Solution is suitable for use in LC/MS or GC/MS methods for clinical toxicology, forensic analysis, or urine drug testing applications.

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Flexeril is a registered trademark of ALZA Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Pictogrammes

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organes cibles

Eyes

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

49.5 °F - closed cup

Point d'éclair (°C)

9.7 °C - closed cup

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Incidence of tricyclic antidepressant-like complications after cyclobenzaprine overdose.
Vikhyat S Bebarta et al.
The American journal of emergency medicine, 30(2), 374-374 (2011-11-22)
Yi Xiang et al.
Biomedical chromatography : BMC, 26(9), 1083-1088 (2011-11-29)
A sensitive, rapid and simple liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS/MS) method was developed for the quantitative determination of cyclobenzaprine in human plasma, to study the pharmacokinetic behavior of cyclobenzaprine capsule in healthy Chinese volunteers. With escitalopram as the internal
Lindsay T Morgan Bicknell et al.
International journal of psychiatry in medicine, 44(4), 305-314 (2012-01-01)
Lamotrigine is FDA-approved as a maintenance treatment of bipolar disorder, but its common off-label uses include bipolar depression and antidepressant augmentation in patients with major depressive disorder. Among other adverse effects, cutaneous reactions, particularly erythema multiforme, are cited as concerns
Harvey Moldofsky et al.
The Journal of rheumatology, 38(12), 2653-2663 (2011-09-03)
To determine the effects of bedtime very low dose (VLD) cyclobenzaprine (CBP) on symptoms and sleep physiology of patients with fibromyalgia (FM), unrefreshing sleep, and the α-nonREM sleep electroencephalographic (EEG) anomaly at screening. Of 37 patients with FM in the
Mona Darwish et al.
Clinical therapeutics, 33(6), 746-753 (2011-06-28)
The single-dose pharmacokinetic profile of cyclobenzaprine extended-release (CER) has been previously characterized and compared with the pharmacokinetics of cyclobenzaprine immediate-release (CIR) administered 3 times daily for 3 doses. The objective of this study was to characterize the multiple-dose pharmacokinetic properties
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique